Takeda shares fall on US delays for alogliptin - update
This article was originally published in Scrip
Executive Summary
Takeda's shares plunged by 13% to close down by the daily limit of ¥500 to ¥3,320 ($33.77) in Tokyo on March 9th, as investors reacted to news of further delays to the US approval of the company's diabetes drug alogliptin.